KMT2A and leukemia: Based on the results of a phase 1 clinical trial in pediatric R/R leukemia patients with MLL-rearrangement, performed between 2014 and 2016 (NCT02141828), administration of EPZ5676 in combination with other antileukemia agents is warranted [150].